Zobrazeno 1 - 10
of 42
pro vyhledávání: '"E. Grandini"'
Autor:
Mario Minichiello, A. Scuteri, Elisabetta Loggi, Fabio Conti, E. Grandini, Giovanni Vitale, Giuliano Furlini, Roberto Di Donato, Silvia Galli, Pietro Andreone, Carmela Cursaro, Stefano Gitto
Publikováno v:
Journal of Clinical Virology. 93:66-70
Background Hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients treated with IFN-free direct acting antiviral (DAA) therapies has recently emerged as a potential risk. Given the potential burden of this issue, further data are needed
Autor:
Lorenzo Badia, C. Puggioli, Pietro Andreone, Michele Pavoni, Pierluigi Viale, Silvia Galli, Maria Letizia Bacchi Reggiani, Ranka Vukotic, Donatella Comparcola, E. Grandini, Carmela Cursaro, Sirio Fiorino, Elisabetta Loggi, Mauro Bernardi, Silvia Maselli, Gabriella Verucchi
Publikováno v:
Liver International. 37:54-61
Background & aims The treatment of chronic hepatitis B infection (CHB) in children is still an area of great uncertainty. Vitamin E is an immunostimulating/antioxidant compound proven to be safe and effective for the treatment of adult CHB. The aim o
Autor:
A. Scuteri, Claudio Borghi, E. Grandini, Giovanni Vitale, Valeria Guarneri, Arrigo F G Cicero, Fabio Conti, Pietro Andreone, Stefano Gitto, Carmela Cursaro, Marina Giovannini, Elisabetta Loggi
Publikováno v:
Annals of Hepatology, Vol 17, Iss 1, Pp 64-75 (2018)
Introduction. Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bce0d3a2825975aef8fc46a85aa30d6
http://hdl.handle.net/11585/622359
http://hdl.handle.net/11585/622359
Autor:
Annagiulia Gramenzi, A. Riili, Mauro Bernardi, E. Grandini, F. Cannoletta, C. Fortini, Elisabetta Loggi, R. Di Donato, A. Scuteri, P. Andreone, Carmela Cursaro
Publikováno v:
Annals of the New York Academy of Sciences. 1194:147-152
The current standard therapy for the treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, although many patients fail to clear the virus and their retreatment options are still unsatisfactory. Thymosin alpha
Autor:
E. Grandini, Ranka Vukotic, Elisabetta Loggi, Silvia Galli, Mauro Bernardi, A. Scuteri, Marzia Margotti, Annagiulia Gramenzi, Giovanni Vitale, Carmela Cursaro, Pietro Andreone
Publikováno v:
Journal of Viral Hepatitis. 15:442-448
Thymosin alpha-1 (Talpha1) has been shown to be effective in chronic hepatitis B treatment. This study investigated the effect of Talpha1 and interferon-alpha (IFNalpha) on cytokine production by peripheral blood mononuclear cells (PBMCs) of 12 patie
Autor:
Alessia Piluso, Cristina Stasi, Pietro Andreone, Fabio Conti, Elisa Fognani, Monica Monti, Elisabetta Loggi, Laura Gragnani, Anna Linda Zignego, Marzia Margotti, E. Grandini
Background and aim: Hepatocellular carcinoma is one of the major causes of death due to cancer worldwide, and its association with hepatitis C virus infection has been definitively established. Hepatitis C virus is also involved in the pathogenesis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6ba8bf02b4aa940f7a44657b395367
http://hdl.handle.net/2158/1084551
http://hdl.handle.net/2158/1084551
Autor:
Valeria Guarneri, Marina Giovannini, Carmela Cursaro, Pietro Andreone, Fabio Conti, A. Scuteri, Elisabetta Loggi, Stefano Gitto, E. Grandini, Giovanni Vitale, Arrigo F G Cicero, Claudio Borghi
Publikováno v:
Atherosclerosis. 263:e185
Autor:
Giuliano Furlini, Mauro Bernardi, Elisabetta Loggi, Silvia Galli, Pietro Andreone, A. Scuteri, E. Grandini, Carmela Cursaro, Claudio Galli, Arianna Martello Panno
Background An early drop of HCV-RNA levels is useful in assessing response to antiviral treatment in chronic hepatitis C; the first recommended time point is 4 weeks after the start of therapy. Objectives We evaluated retrospectively HCV-RNA and HCVA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d112d9ecd3af07c97c55dc6c7ebede6e
http://hdl.handle.net/11585/133622
http://hdl.handle.net/11585/133622
Autor:
Valeria Guarneri, Ranka Vukotic, Silvia Galli, E. Grandini, Pietro Andreone, M. Stanzani, Marzia Margotti, Elisabetta Loggi, M.P. Landini, A. Scuteri, Giuliano Furlini, Carmela Cursaro, Claudio Galli
Publikováno v:
Digestive and Liver Disease. 48:e61
End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0035b1f3e753ba2358665a95ba496499
https://europepmc.org/articles/PMC2738783/
https://europepmc.org/articles/PMC2738783/